MASLD/MASH: Advances & Gaps in Care & Treatment

The escalating global metabolic crisis is fundamentally reshaping the landscape of liver disease, with metabolic dysfunction-associated steatohepatitis (MASH) now a dominant clinical challenge. A recent comprehensive review published in Annals of Medicine doesn’t just catalog the advances of the last two decades in understanding and managing this condition – it underscores a critical inflection point. We’re moving beyond simply recognizing the problem to actively seeking and implementing solutions, driven by a confluence of rising prevalence, improved diagnostics, and a burgeoning pipeline of targeted therapies. This isn’t merely a medical story; it’s a public health and economic one, given the disease’s strong correlation with obesity, type 2 diabetes, and metabolic syndrome, impacting an estimated 25% of the global population.

For years, nonalcoholic fatty liver disease (NAFLD) was a somewhat nebulous diagnosis, often discovered incidentally. The renaming to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and its progressive form, MASH, reflects a crucial understanding: this isn’t simply fat in the liver, but a manifestation of systemic metabolic derangement. This reclassification, finalized in 2023, has spurred a more focused approach to diagnosis and treatment. The historical reliance on liver biopsy – an invasive and often impractical procedure – has been a major bottleneck. The review highlights the growing utility of non-invasive methods like high-resolution CT, MRI, magnetic resonance elastography, and increasingly sophisticated blood-based scoring systems (FIB-4, FAST, Agile scores, ELF testing). These tools allow for better risk stratification and monitoring, potentially reducing the need for biopsies in many cases.

The therapeutic landscape is also undergoing a rapid transformation. While lifestyle modifications – particularly Mediterranean-style diets, calorie restriction, and regular physical activity – remain the cornerstone of management, the review details promising developments in pharmacologic interventions. Resmetirom, a thyroid hormone receptor β agonist, has demonstrated significant improvements in fibrosis and disease resolution in Phase 3 trials, and represents a potential first-in-class therapy. Other drug classes targeting insulin resistance, lipid metabolism, and inflammation are also showing promise. However, the authors rightly caution that long-term safety and durability of response need further investigation.

The Forward Look

The progress outlined in this review isn’t the finish line, but rather a springboard for further innovation. The biggest challenge now lies in translating these advances into real-world clinical practice. We can expect to see increased adoption of non-invasive diagnostic tools, but standardization and validation across diverse populations will be critical. The emergence of effective pharmacotherapies will necessitate the development of clear treatment algorithms and patient selection criteria. Furthermore, the focus will likely shift towards personalized medicine, tailoring treatment strategies based on individual metabolic profiles and disease severity.

A key area to watch is the integration of artificial intelligence (AI) and machine learning (ML) in both diagnosis and prognosis. AI algorithms could potentially analyze complex datasets – including imaging, blood biomarkers, and clinical information – to identify patients at high risk of progression and predict treatment response. The authors’ call for multidisciplinary collaboration is particularly prescient. Effective MASLD/MASH management will require close coordination between hepatologists, endocrinologists, cardiologists, dietitians, and behavioral health specialists. Finally, the economic implications of widespread MASLD/MASH screening and treatment will need careful consideration, particularly in resource-constrained healthcare systems. Expect increased scrutiny from payers regarding the cost-effectiveness of new diagnostic and therapeutic interventions.

References

1. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223-238. doi:10.1038/s41575-020-00381-6
2. Wang D, Miao J, Zhang L, Zhang L. Research advances in the diagnosis and treatment of MASLD/MASH. Ann Med. 2025;57(1):2445780. doi:10.1080/07853890.2024.2445780
3. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi:10.1002/hep.28431